Arbutus Biopharma Corporation (ABUS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Arbutus Biopharma Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Arbutus Biopharma Corporation (ABUS) has returned -6.44% so far this year and 28.94% over the past 12 months. Over the last ten years, ABUS has returned 0.76% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Aug 3, 2015, ABUS's average daily return is +0.10%, while the average monthly return is +1.67%. At this rate, your investment would double in approximately 3.5 years.

Historically, 48% of months were positive and 52% were negative. The best month was Jul 2020 with a return of +109.3%, while the worst month was Mar 2020 at -65.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ABUS closed higher 45% of trading days. The best single day was Jul 23, 2020 with a return of +119.9%, while the worst single day was Mar 27, 2020 at -46.5%.

Arbutus Biopharma Corporation has an annualized alpha of 12.59%, beta of 1.01, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since August 04, 2015.

• This stock participated in 187.93% of S&P 500 Index downside but only 130.10% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ABUS ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Arbutus Biopharma Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arbutus Biopharma Corporation was 92.96%, occurring on Oct 9, 2019. The portfolio has not yet recovered.

The current Arbutus Biopharma Corporation drawdown is 63.56%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Arbutus Biopharma Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Arbutus Biopharma Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.